albendazole tablet brand name Formulation and Performance Analysis-NEWS-Dingzhou Kangquan Pharmaceutical - Professional Veterinary Medicine Manufacturer

Introduction

Albendazole tablets, branded as [brand name], represent a crucial anthelmintic medication within the pharmaceutical industry, specifically categorized as a benzimidazole derivative. Its technical position lies within the broader spectrum of parasitic disease treatment, serving as a first-line therapeutic agent against a wide range of intestinal parasites in both human and veterinary medicine. The core performance characteristics revolve around its broad-spectrum efficacy, achieved through selective inhibition of microtubule polymerization in parasitic cells, disrupting their glucose uptake and ultimately leading to their immobilization and death. A key pain point within pharmaceutical manufacturing is ensuring consistent bioavailability and stability of the active pharmaceutical ingredient (API), albendazole, during formulation and storage. Bioavailability, particularly, is a significant concern due to the poor aqueous solubility of albendazole, necessitating strategies to enhance dissolution and absorption. Furthermore, maintaining API integrity against degradation pathways, such as oxidation and hydrolysis, is paramount to guarantee therapeutic effectiveness and adherence to stringent regulatory guidelines.

Material Science & Manufacturing

The primary raw material, albendazole (C₁₂H₁₅N₃O₂S), is a thiocarbamate derivative. Its physical properties are critical to formulation: it’s a white to off-white powder, practically insoluble in water, soluble in dimethyl sulfoxide, and sparingly soluble in ethanol. Manufacturing commences with the synthesis of albendazole API, typically involving multi-step organic synthesis routes originating from 5-chlorobenzimidazole. Key parameters during synthesis include maintaining precise temperature control to minimize unwanted by-product formation and rigorous purification techniques, such as recrystallization, to achieve pharmaceutical-grade purity (typically >99%). Tablet formulation involves several processes: blending the API with excipients (microcrystalline cellulose, sodium starch glycolate, povidone, magnesium stearate, etc.), granulation (wet granulation being common to improve flowability and compressibility), tablet compression, and finally, coating (often with a polymer film to enhance stability and patient compliance). Tablet compression forces, dwell time, and punch/die dimensions are critical parameters controlled during manufacturing, directly impacting tablet hardness, disintegration time, and drug release profile. Chemical compatibility between albendazole and excipients is assessed rigorously to prevent degradation or interactions that could compromise drug efficacy. Excipient selection focuses on inertness and compatibility with albendazole's physical and chemical properties.

Performance & Engineering

The performance of [brand name] albendazole tablets is fundamentally linked to its in vivo pharmacokinetic and pharmacodynamic properties. Bioavailability is a primary engineering challenge; the low aqueous solubility results in erratic and incomplete absorption. Formulation strategies, such as particle size reduction, solid dispersions, and complexation with cyclodextrins, aim to enhance dissolution rates. Force analysis during tablet compression is crucial, requiring careful balancing between tablet hardness (resistance to breakage) and disintegration time (speed of breakdown in the gastrointestinal tract). Environmental resistance is assessed through stability studies, evaluating degradation under varying temperature, humidity, and light exposure conditions. Compliance requirements mandated by regulatory bodies (FDA, EMA, etc.) dictate stringent quality control procedures, including assaying API content, dissolution testing, and impurity profiling. The drug’s mechanism of action involves binding to β-tubulin, inhibiting microtubule polymerization. This disrupts glucose uptake, leading to energy depletion and eventual parasite death. Understanding this mechanism informs in vitro susceptibility testing to monitor for potential resistance development in parasite populations. The degradation pathways of albendazole include oxidation, hydrolysis, and photolysis, necessitating appropriate packaging (e.g., blister packs with aluminum foil) and storage conditions to protect the API from these environmental stressors.

Technical Specifications

Parameter	Specification	Test Method	Acceptance Criteria
Assay (Albendazole Content)	98.0% - 102.0%	HPLC	Conforms to USP standards
Related Substances (Impurities)	Individual impurity < 0.1%, Total impurities < 0.5%	HPLC	Complies with regulatory limits
Dissolution (Q15 min)	≥ 75%	USP Apparatus II	Meets established dissolution profile
Water Content	≤ 0.5%	Karl Fischer Titration	Within specified range
Hardness	4-8 kg force	Tablet Hardness Tester	Tablets do not crumble during handling
Friability	≤ 0.8%	Friabilator	Minimal tablet erosion during transport

Failure Mode & Maintenance

Failure modes for [brand name] albendazole tablets primarily revolve around degradation of the API leading to sub-potency or formation of toxic degradation products. Common failure mechanisms include: 1) Oxidation: Exposure to oxygen can lead to oxidation of the sulfur atom in albendazole, reducing its efficacy. 2) Hydrolysis: Moisture ingress can catalyze hydrolytic degradation, especially during long-term storage in humid environments. 3) Photolysis: Exposure to light can initiate photochemical degradation pathways. 4) Physical Instability: Tablets can experience chipping, cracking, or crumbling due to inadequate hardness or poor handling during manufacturing or transport. 5) Bioavailability Issues: Poor dissolution due to inadequate formulation or excipient interactions. Maintenance solutions involve: a) Controlled Storage: Storage in cool, dry, and dark conditions. Use of desiccants in packaging to minimize moisture exposure. b) Protective Packaging: Employing blister packs with aluminum foil to shield against light and moisture. c) Formulation Optimization: Utilizing excipients that enhance API stability and dissolution. d) Regular Stability Testing: Performing periodic stability studies to monitor API content and impurity profiles throughout the shelf life. e) Process Control: Maintaining tight control over manufacturing parameters, such as granulation, compression, and coating, to ensure consistent tablet quality. Addressing bioavailability issues often necessitates reformulation strategies, such as micronization or the use of solubilizing agents.

Industry FAQ

Q: What are the critical quality attributes (CQAs) for albendazole tablets, and how are they monitored?

A: The CQAs include assay (API content), related substances (impurity profile), dissolution rate, water content, hardness, and friability. These are monitored through rigorous analytical testing performed at each batch release, utilizing validated methods like HPLC, Karl Fischer titration, and standardized physical tests (hardness and friabilator). Trending of CQA data over time is crucial for process monitoring and identifying potential deviations.

Q: How does particle size of the albendazole API affect bioavailability?

A: Albendazole has very low aqueous solubility. Smaller particle size significantly increases the surface area exposed to the dissolution medium, leading to enhanced dissolution rates and improved bioavailability. Micronization is often employed to reduce particle size and improve drug absorption.

Q: What excipients are commonly used in albendazole tablet formulations, and what roles do they play?

A: Common excipients include microcrystalline cellulose (MCC) as a diluent and binder, sodium starch glycolate as a disintegrant, povidone (PVP) as a binder, and magnesium stearate as a lubricant. MCC provides bulk and compressibility, sodium starch glycolate promotes tablet breakdown, PVP improves cohesive strength, and magnesium stearate facilitates tablet ejection from the die.

Q: What are the key stability considerations for albendazole tablets during long-term storage?

A: The primary stability concerns are oxidation, hydrolysis, and photolysis. Storage in controlled conditions (cool, dry, and dark) and packaging in moisture-resistant and light-protective materials (e.g., blister packs) are essential. Stability studies conducted according to ICH guidelines are crucial to determine shelf life and recommended storage conditions.

Q: How do you ensure compliance with regulatory requirements (e.g., FDA, EMA) during the manufacturing of albendazole tablets?

A: Compliance is ensured through adherence to Good Manufacturing Practices (GMP), comprehensive documentation, validated analytical methods, robust quality control procedures, and regular audits by regulatory agencies. Batch records, deviations, change controls, and CAPA (Corrective and Preventive Action) systems are meticulously maintained and reviewed.

Conclusion

Albendazole tablets, branded as [brand name], represent a complex pharmaceutical formulation demanding stringent control over material science, manufacturing processes, and quality assurance procedures. The inherent challenges related to the poor aqueous solubility of albendazole necessitate advanced formulation strategies to optimize bioavailability and ensure consistent therapeutic efficacy. Maintaining API stability against degradation pathways, driven by environmental factors, is paramount for product quality and patient safety.

Future advancements in albendazole tablet technology will likely focus on novel drug delivery systems, such as nanocrystals, solid lipid nanoparticles, or amorphous solid dispersions, to further enhance dissolution and absorption. Continuous process verification and real-time release testing (RTRT) will play an increasingly important role in streamlining manufacturing and ensuring consistent product quality. The ongoing challenge of parasitic resistance necessitates continued research and development of new anthelmintic agents and strategies to combat resistance mechanisms.

Apr . 01, 2024 17:55 Back to list

albendazole tablet brand name Formulation and Performance Analysis